Sign inJoin waitlistJoin the waitlist

Jaykumar Thumar

Physician · Hartford Hospital

Credentials: · · ·

History

Hartford Hospital · William W Backus Hospital
2023–Present

Hematology and Medical Oncology
University of Connecticut School of Medicine
2008–2011
Yale-New Haven Hospital
2005–2008
Government Medical College
2002–2003
B J MED COLL, GUJARAT UNIV, AHMEDABAD, GUJARAT
1998–2002

Research

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Journal of Clinical Oncology · 2019 · 274 citations
Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry
Molecular & Cellular Proteomics · 2007 · 133 citations
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
Review · Medical Oncology · 2013 · 115 citations

Howard Hochster
4 papers
Jill Lacy
4 papers
Harriet Kluger
3 papers
Jeremy Kortmansky
3 papers
Stacey Stein
3 papers · 1 as a fellow
EC
Elena Chiorean
2 papers
MH
Matthew Hadfield
2 papers · 2 as a resident
Michael Cecchini
2 papers
Neal Fischbach
2 papers
Philip Philip
2 papers
Aaron Scott
1 paper
AJ
Adham Jurdi
1 paper

Clinical trials

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Site PI · Recruiting · Phase 2
Philogen S.p.A.
2024–2028
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
VM Oncology, LLC
2018–2028